ChAdOx1 nCoV-19疫苗接种后抗血小板因子4抗体实验室检测方法的评估
本研究评估了英国市售的多种抗PF4抗体检测方法在43例疑似VITT患者中的表现。结果显示,快速检测法和化学发光法对VITT的敏感性不如ELISA,且单一ELISA无法检出所有可能/ probable VITT病例;临床高度怀疑时,若一种ELISA阴性,应考虑第二种ELISA或血小板活化试验。
要点
- 快速检测法和化学发光法对VITT敏感性差,不适用于排除VITT。
- IgG特异性ELISA与多特异性ELISA对VITT敏感性无差异。
- 单一ELISA阴性但临床高度怀疑VITT时,应加做第二种ELISA或血小板活化试验。
核心结论
- HemosIL AcuStar HIT-IgG、HemosIL HIT-Ab、Diamed PaGIA gel和STic Expert检测对VITT的敏感性低于ELISA。
- IgG-ELISA与多特异性ELISA对VITT的敏感性无优劣之分。
- 没有单一ELISA方法能检出所有可能/ probable VITT病例。
研究设计与样本
- 对来自英国43例疑似VITT患者的样本进行检测评估,病例经英国专家血液学小组多学科团队分类为不太可能、可能或很可能VITT。
- 评估了4种IgG特异性ELISA、2种多特异性ELISA和4种快速检测法。
主要发现
- HemosIL AcuStar HIT-IgG、HemosIL HIT-Ab、Diamed PaGIA gel和STic Expert检测对VITT的敏感性差。
- 未证明IgG-ELISA在VITT敏感性上优于多特异性ELISA。
- 没有单一ELISA方法能检出所有可能/ probable VITT病例。
关键数值与推荐
- 疑似VITT样本应进行ELISA检测,因快速检测法和化学发光法敏感性差。
- 若单一ELISA检测阴性但临床高度怀疑VITT,应考虑第二种ELISA或血小板活化试验。
临床怎么用
- 实验室在收到疑似VITT检测请求时,应确保进行ELISA检测,而非仅用快速检测法或化学发光法。
- 临床高度怀疑VITT而一种ELISA阴性时,应追加第二种ELISA或血小板活化试验。
局限性
- 研究仅评估了英国市售的检测方法。
- 样本来自疑似VITT患者,未在更广泛人群中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Vaccine-induced immune thrombocytopenia and thrombosis (VITT) following ChAdOx1 nCOV-19 vaccine has been described, associated with unusual site thrombosis, thrombocytopenia, raised D-dimer, and high-titer immunoglobulin-G (IgG) class anti-platelet factor 4 (PF4) antibodies. Enzyme-linked immunosorbent assays (ELISA) have been shown to detect anti-PF4 in patients with VITT, but chemiluminescence assays do not reliably detect them. ELISA assays are not widely available in diagnostic laboratories, and, globally, very few laboratories perform platelet activation assays. METHODS: Assays that are commercially available in the United Kingdom were evaluated for their ability to identify anti-PF4 antibodies in samples from patients with suspected VITT. Four IgG-specific ELISAs, two polyspecific ELISAs, and four rapid assays were performed on samples from 43 patients with suspected VITT from across the United Kingdom. Cases were identified after referral to the UK Expert Haematology Panel multidisciplinary team and categorized into unlikely, possible, or probable VITT. RESULTS AND DISCUSSION: We demonstrated that the HemosIL AcuStar HIT-IgG, HemosIL HIT-Ab, Diamed PaGIA gel, and STic Expert assays have poor sensitivity for VITT in comparison to ELISA. Where these assays are used for heparin-induced thrombocytopenia (HIT) diagnosis, laboratories should ensure that requests for suspected VITT are clearly identified so that an ELISA is performed. No superiority of IgG-ELISAs over polyspecific ELISAs in sensitivity to VITT could be demonstrated. No single ELISA method detected all possible/probable VITT cases; if a single ELISA test is negative, a second ELISA or a platelet activation assay should be considered where there is strong clinical suspicion.
引用
- Platton S, Bartlett A, MacCallum P, et al. Evaluation of laboratory assays for anti-platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccination. J Thromb Haemost. 2021. PMID: 33973336. doi:10.1111/jth.15362
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。